
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is positioned to see significant growth in the coming years driven by potential blockbuster drugs in its pipeline, including sotatercept, admilparant, and milvexian. The company's guidance, recent positive clinical trial results, and increased confidence in its transformative potential from experts in various therapeutic areas are key reasons for the analyst's positive outlook. With strong growth potential and a solid dividend, Bristol-Myers Squibb presents an attractive investment opportunity for investors.
Bears say
Bristol-Myers Squibb is expected to have a solid quarter due to strong sales of growth products such as Opdivo/Qvantig, Camzyos, and Reblozyl, and continued growth for Eliquis. However, upcoming clinical readouts and label expansions for key drugs like milvexian (SPAF/SSP), admilparant (IPF), and Cobenfy (ADP) may bring about a unique multiple expansion opportunity and drive further investor interest. Risks to this outlook include potential competition in rare CV, I&I and oncology markets, clinical failures, and regulatory delays.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares